TCBP - TC BioPharm (Holdings) plc

0.5
-1.040   -208.000%

Share volume: 1,955,586
Last Updated: 03-21-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.19%

PREVIOUS CLOSE
CHG
CHG%
$1.54
-1.04
-0.68%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
-74.36%
2 Year
-52.38%
Key data
Stock price
$0.50
P/E Ratio 
0.00
DAY RANGE
$0.50 - $1.54
EPS 
N/A
52 WEEK RANGE
$0.50 - $2.25
52 WEEK CHANGE
-$71.91
MARKET CAP 
2.888 M
YIELD 
N/A
SHARES OUTSTANDING 
518.463 K
DIVIDEND
$0.00
EX-DIVIDEND DATE
02-10-2025
NEXT EARNINGS DATE
05-21-2025
BETA 
-1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Bryan Kobel
Region: US
Website: tcbiopharm.com
Employees: 80
IPO year: 2022
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

TC Biopharm (Holdings) Plc focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia.

Recent news